Docetaxel News and Research

RSS

Docetaxel is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of breast and non-small cell lung cancer (NSCLC). It is also approved to be used with other drugs to treat squamous cell carcinoma of the head and neck (SCCHN) and certain types of gastric and prostate cancer.

Docetaxel is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent.

Spectrum Pharmaceuticals to present data on Ortataxel in breast cancer at major oncology meeting

Spectrum Pharmaceuticals, Inc., will present Phase 2 data on ortataxel at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting being held May 30 to June 3, 2008 at the McCormick Place Convention Center in Chicago, Illinois.

19 May 2008

Discovery of protein that helps predict prostate cancer survival

An Oregon Health & Science University Cancer Institute researcher has identified a protein that is a strong indicator of survival for men with advanced prostate cancer. The C-reactive protein, also known as CRP, is a special type of protein produced by the liver that is elevated in the presence of inflammation.

22 Apr 2008

Herceptin and chemotherapy improves response rates without major adverse effects in HER2 breast cancer

Women with a particularly aggressive form of breast cancer seem to do better if they are treated with a combined anthracycline and taxane chemotherapy regimen before surgery, together with trastuzumab (Herceptin) before and after surgery, according to results from the largest multi-centre trial to investigate this treatment.

18 Apr 2008

New type of drug shrinks primary breast cancer tumours significantly in just six weeks

A drug that targets the cell surface receptors that play an important role in many types of cancer can bring about significant tumour regression in breast cancer after only six weeks of use, a scientist told the 6th European Breast Cancer Conference (EBCC-6) (Thursday 17 April).

17 Apr 2008

AstraZeneca completes enrollment in phase III studies of cancer drug vandetanib

AstraZeneca has announced that it has completed patient enrollment in two pivotal Phase III studies for vandetanib, the company's investigational, once-daily oral anti-cancer drug, for the second-line treatment of non-small cell lung cancer (NSCLC).

13 Mar 2008

Protein that stimulates blood vessel growth worsens ovarian cancer

A protein that stimulates blood vessel growth worsens ovarian cancer, but its production can be stifled by a tiny bit of RNA wrapped in a fatty nanoparticle, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Journal of the National Cancer Institute.

27 Feb 2008

OHSU Cancer Institute research gives hope for chemo holidays for men with advanced prostate cancer

Oregon Health & Science University Cancer Institute researchers, in a first-of-its-kind study, have found that even men with advanced prostate cancer can take a much-needed safe break, or holiday, from chemotherapy.

27 Feb 2008

Avastin cancer drug does well in breast cancer study

A new study on the cancer drug Avastin has found that when the drug is combined with chemotherapy it slowed down the progression of breast cancer.

13 Feb 2008

Docetaxel given after doxorubicin reduces recurrence

Adding the drug docetaxel to anthracycline-based chemotherapy slightly improved disease-free survival in breast cancer patients, according to a randomized clinical trial published online January 8 in the Journal of the National Cancer Institute.

9 Jan 2008

Explanation on resistance to taxane class of drugs

Scientists have uncovered critical new details about the mechanisms that modulate the response of ovarian cancer cells to chemotherapy.

10 Dec 2007

FDA approves approved Ixempra (ixabepilone) for advanced breast cancer

The U.S. Food and Drug Administration has approved Ixempra (ixabepilone), a new anti-cancer treatment, for use in patients with metastatic or locally advanced breast cancer who have not responded to certain other cancer drugs.

22 Oct 2007

Taxol-type drugs give slight boost to survival rates in early breast cancer

The breast cancer drugs called taxanes, which include Taxol (paclitaxel) and Taxotere (docetaxel), increase survival rates when used as part of chemotherapy following surgery for cancers that have not spread, according to a new review of the research.

17 Oct 2007

Taxotere (docetaxel) granted FDA approval to treat locally advanced head and neck cancer prior to chemo and surgery

Sanofi-aventis announced that the U.S. Food and Drug Administration (FDA) has approved Taxotere (docetaxel) Injection Concentrate in combination with cisplatin and 5-fluorouracil for induction therapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN) before patients undergo chemoradiotherapy and surgery.

2 Oct 2007

Genomic profiling of lung tumors helps doctors choose most effective treatment

Determining the genetic profile of a particular lung tumor can help clinicians make the crucial decision about which chemotherapy treatment to try first.

29 Sep 2007

Survival data presented from phase II study of hormone-resistant prostate cancer patients

The results from the randomized, double -blind, placebo -controlled, Phase II EPOC (Endothelin A Proof Of Concept) Study of ZD4054 - a specific endothelin A (ETA) receptor antagonist – were delivered at the 14th European Congress of Clinical Oncology (ECCO, 23-27 September, Barcelona).

26 Sep 2007

New AstraZeneca compound shows promoise for hormone resistant prostate cancer patients with bone metastases

New Phase II data suggests that ZD4054, a novel compound in development for the treatment of men with Hormone Resistant Prostate Cancer (HRPC), could offer a promising improvement in overall survival in men with metastatic HRPC who were asymptomatic or mildly symptomatic for pain.

26 Sep 2007

PET scans accurately detect a breast tumor's response to chemotherapy

Researchers in Australia have shown that positron emission tomography (PET) that uses a radioactive sugar molecule is more useful than mammography and ultrasound in predicting a breast tumour's response to chemotherapy and, therefore, the patient's ultimate likelihood of survival.

26 Sep 2007

BRCA1 gene plays significant role in non-small cell lung cancer

Barcelona, Spain: Researchers have found that the breast cancer susceptibility gene, BRCA1, plays a significant role in non-small cell lung cancer (NSCLC).

25 Sep 2007

Some cancer cells mimic stem cells to evade chemotherapy

Anti-cancer treatments often effectively shrink the size of tumors, but some might have an opposite effect, actually expanding the small population of cancer stem cells believed to drive the disease, according to findings presented Sept. 19 by Vasyl Vasko, M.D. Ph.D., a pathologist at the Uniformed Services University of the Health Sciences (USU) at the American Association for Cancer Research's second International Conference on Molecular Diagnostics in Cancer Therapeutic Development.

25 Sep 2007

Molecular fingerprint of breast cancer drug resistance can predict response to treatment

A way of predicting which patients will respond well to treatment with a common chemotherapy drug used in breast cancer was unveiled at the European Cancer Conference (ECCO 14).

25 Sep 2007

Docetaxel News and Research

Further Reading

Spectrum Pharmaceuticals to present data on Ortataxel in breast cancer at major oncology meeting

Discovery of protein that helps predict prostate cancer survival

Herceptin and chemotherapy improves response rates without major adverse effects in HER2 breast cancer

New type of drug shrinks primary breast cancer tumours significantly in just six weeks

AstraZeneca completes enrollment in phase III studies of cancer drug vandetanib

Protein that stimulates blood vessel growth worsens ovarian cancer

OHSU Cancer Institute research gives hope for chemo holidays for men with advanced prostate cancer

Avastin cancer drug does well in breast cancer study

Docetaxel given after doxorubicin reduces recurrence

Explanation on resistance to taxane class of drugs

FDA approves approved Ixempra (ixabepilone) for advanced breast cancer

Taxol-type drugs give slight boost to survival rates in early breast cancer

Taxotere (docetaxel) granted FDA approval to treat locally advanced head and neck cancer prior to chemo and surgery

Genomic profiling of lung tumors helps doctors choose most effective treatment

Survival data presented from phase II study of hormone-resistant prostate cancer patients

New AstraZeneca compound shows promoise for hormone resistant prostate cancer patients with bone metastases

PET scans accurately detect a breast tumor's response to chemotherapy

BRCA1 gene plays significant role in non-small cell lung cancer

Some cancer cells mimic stem cells to evade chemotherapy

Molecular fingerprint of breast cancer drug resistance can predict response to treatment

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News